1 Broadway # 14, Cambridge, MA 02142
The first indication for SDX-7320 is in post-menopausal HR+, Her2- metastatic breast cancer patients with the PIK3CA mutation in combination with standard of care treatment (Piqray, or other new agents). Patients at high risk for hyperglycemia with Piqray typically have baseline metabolic dysfunction. We are currently planning on enrolling this Phase 1b/2 combination study in early 2021.
Clinical trials for other indications (e.g., triple-negative breast cancer (TNBC), prostate cancer, metastatic colorectal cancer, hepatacellular carcinoma (liver cancer), NSCLC) will follow later in 2021.